REGENXBIO is a gene therapy company built around its NAV AAV (adeno-associated virus) vector platform for delivering genetic medicines. It develops its own pipeline—often focused on retinal, neuromuscular, and metabolic diseases—and licenses vector technology and manufacturing know-how to other biopharma partners. The model mixes product development with platform and licensing economics rather than traditional small-molecule drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 21.4 | — | -70.9 | — |
| Q3 2025 | 29.7 | — | -61.9 | — |
| Q4 2025 | 30.3 | — | -67.2 | — |
| Q1 2026 | 6.4 | — | -90 | — |
| Q2 2026 | 108 | 405.7% | 22.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Autolus Therapeutics plc (AUTL), VersaBank (VBNK), Cytek Biosciences, Inc. (CTKB), Crescent Biopharma, Inc. (CBIO), ASP Isotopes Inc. (ASPI), The Honest Company, Inc. (HNST)